You are here: Industry Insights > Ovid

News List

Healx secures option to license rights from Ovid to develop gaboxadol pharmaceutical-business-review
February 09, 2022
Healx, an AI-powered, technology company involved in the next generation of drug discovery...
Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline pharmaceutical-business-review
January 04, 2022
ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
AstraZeneca, Ovid Therapeutics Partner Against Epilepsy contractpharma
January 03, 2022
Transaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines.
Takeda secures global rights to develop and commercialise soticlestat pharmaceutical-business-review
March 09, 2021
Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic ...
Ovid and UConn Enter Strategic Research Collaboration contractpharma
July 24, 2020
Aim to accelerate the development of next-gen genetic therapy for Angelman Syndrome.
Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
July 14, 2020
To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.
Ovid posts results from midstage rare disease test, plots registrational path fiercebiotech
August 07, 2018
Ovid Therapeutics has posted a batch of topline data out of its midstage STARS trial in Angelman syndrome as it seeks out a path to approval.